Retro Biosciences is a clinical-stage longevity biotech in Redwood City, California with a single, unsubtle goal: add ten healthy years to the human lifespan. Founded in 2018 and launched publicly in 2021 with $180 million from OpenAI CEO Sam Altman, the company attacks aging at the cellular level across three platforms - autophagy enhancement, cellular reprogramming, and plasma-inspired therapeutics. Its lead drug, RTR242, an autophagy-restoring small molecule aimed at Alzheimer's disease, entered a first-in-human Phase 1 trial in 2025. A 2026 raise valued Retro at $1.8 billion.
Dugal Bain-Kim is the co-founder and CEO of Lifeforce, a clinically integrated health optimization platform he launched in February 2022 with Tony Robbins, Dr. Peter Diamandis and Joel Jackson. An Australian-born finance and healthcare operator who went from BlackRock and Cambridge to telehealth, he built Lifeforce after his own fragmented hunt for answers about his changing body at 38. The company tests 40+ biomarkers via at-home blood draws and pairs the data with clinicians, coaching and supplements, on a stated mission to extend healthy lifespan for five million people by 2030.
Joe Betts-LaCroix is the co-founder and CEO of Retro Biosciences, a San Francisco longevity biotech on a mission to add 10 healthy years to the human lifespan. A scientist-turned-serial-entrepreneur who once held a Guinness World Record for building the world's smallest Windows PC, he now leads a company backed by OpenAI's Sam Altman, valued at $1.8 billion in 2026, that has run an Alzheimer's clinical trial and co-developed a longevity-focused AI model with OpenAI. He came to biology by an unlikely route: a D-average high schooler who tinkered in shared houses, then earned straight A's, transferred to Harvard, and did research at MIT and Caltech before co-discovering principles of electron transfer in proteins.
Hone Health is a New York-based telemedicine clinic built for preventive and longevity care. It pairs at-home and in-person testing of 40+ biomarkers with physician-guided treatment plans for hormone optimization, menopause, weight loss, sexual health, thyroid and more, delivered nationwide on a subscription model starting around $129/month. After raising a $33M Series A in January 2025 and acquiring in-home care company ivee, Hone has tested 300,000+ patients and treats roughly 55,000 active members.
Maxim (Max) Kholin is the co-founder and COO of Gero, a physics-powered longevity biotech company applying statistical physics and AI to crack the biology of aging. With roots in contract law, international business, and computational drug design, he bridges the gap between cutting-edge science and real-world commercialization. Gero - which he co-founded with physicist Peter Fedichev in 2015 - has pioneered the field of 'Gerophysics,' trained its models on 100M+ longitudinal medical records, and secured partnerships with Pfizer and Chugai Pharmaceutical worth up to $250M in milestones. Based across Singapore and Palo Alto, Kholin's mission is nothing less than transforming humans into a non-aging species.
Peter H. Diamandis is a Greek-American entrepreneur, physician, and futurist who has founded or co-founded 25+ companies and is best known as the creator of the XPRIZE Foundation - which has launched over $600 million in incentive competitions catalyzing $10+ billion in R&D. A data-driven optimist, he co-founded Singularity University with Ray Kurzweil, runs the Metatrends newsletter (157,000+ subscribers), and is a 4x New York Times bestselling author. His current mission centers on longevity - he launched the $101 million XPRIZE Healthspan in 2024 and published the Longevity Guidebook in January 2025.